Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabTAXONERA, C; ESTELLES, J; GISBERT, J. P et al.Alimentary pharmacology & therapeutics. 2011, Vol 33, Num 3, pp 340-348, issn 0269-2813, 9 p.Article

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapyLORAS, C; GISBERT, J. P; VIDA, L et al.Gut. 2010, Vol 59, Num 10, pp 1340-1346, issn 0017-5749, 7 p.Article

Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre studyCHAPARRO, M; BURGUENO, P; GOMEZ SENENT, S et al.Alimentary pharmacology & therapeutics. 2012, Vol 35, Num 2, pp 275-283, issn 0269-2813, 9 p.Article

Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot studyDOMENECH, E; HINOJOSA, J; ESTEVE-COMAS, M et al.Alimentary pharmacology & therapeutics. 2004, Vol 20, Num 11-12, pp 1347-1352, issn 0269-2813, 6 p.Article

Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab : a prospective, open-label, multicentre trialHINOJOSA, J; GOMOLLON, F; GARCIA, S et al.Alimentary pharmacology & therapeutics. 2007, Vol 25, Num 4, pp 409-418, issn 0269-2813, 10 p.Article

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsLANAS, A; GARCIA-RODRIGUEZ, L. A; GÜELL, M et al.Gut. 2006, Vol 55, Num 12, pp 1731-1738, issn 0017-5749, 8 p.Article

Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel diseaseBASTIDA, G; NOS, P; AGUAS, M et al.Alimentary pharmacology & therapeutics. 2005, Vol 22, Num 9, pp 775-782, issn 0269-2813, 8 p.Article